Taylor Lorenz @TaylorLorenz
@ZlattyDottie @_bahhumbug Yeah, it’s definitely worth getting if you’re able and qualify. But worth noting it doesn’t hold up against rising variants :( — PolitiTweet.org
Ben Murrell @BenjMurrell
In terms of clinical monoclonal antibodies, Evusheld is completely gone for BA.2.75.2. Sotrovimab looks similar bet… https://t.co/g9M0H2f7Tb